{Reference Type}: Journal Article
{Title}: Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.
{Author}: Xu AY;Velásquez GE;Zhang N;Chang VK;Phillips PP;Nahid P;Dorman SE;Kurbatova EV;Whitworth WC;Sizemore E;Bryant K;Carr W;Brown NE;Engle ML;Nhung NV;Nsubuga P;Diacon A;Dooley KE;Chaisson RE;Swindells S;Savic RM; ;
{Journal}: Am J Respir Crit Care Med
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 16
{Factor}: 30.528
{DOI}: 10.1164/rccm.202401-0165OC
{Abstract}: <B>BACKGROUND: </B>Optimizing pyrazinamide dosing is critical to improve treatment efficacy while minimizing toxicity during tuberculosis treatment. Study 31/ACTG A5349 represents the largest Phase 3 randomized controlled therapeutic trial to date for such investigation.<BR><B>OBJECTIVE: </B>We sought to report pyrazinamide pharmacokinetic parameters, risk factors for lower pyrazinamide exposure, and relationships between pyrazinamide exposure with efficacy and safety outcomes. We aimed to determine pyrazinamide dosing strategies that optimize risks and benefits.<BR><B>METHODS: </B>We analyzed pyrazinamide steady-state pharmacokinetic data using population nonlinear mixed-effects models. We evaluated the contribution of pyrazinamide exposure to long-term efficacy using parametric time-to-event models and safety outcomes using logistic regression. We evaluated optimal dosing with therapeutic windows targeting ≥95% durable cure and safety within the observed proportion of the primary safety outcome.<BR><B>RESULTS: </B>Among 2255 participants with 6978 plasma samples, pyrazinamide displayed 7-fold exposure variability (151-1053 mg·h/L). Body weight was not a clinically relevant predictor of drug clearance and thus did not justify the need for weight-banded dosing. Both clinical and safety outcomes were associated with pyrazinamide exposure, resulting in a therapeutic window of 231-355 mg·h/L for the control and 226-349 mg·h/L for the rifapentine-moxifloxacin regimen. Flat dosing of pyrazinamide at 1000 mg would have permitted an additional 13.1% (n=96) participants allocated to the control and 9.2% (n=70) to the rifapentine-moxifloxacin regimen dosed within the therapeutic window, compared to the current weight-banded dosing.<BR><B>CONCLUSIONS: </B>Flat dosing of pyrazinamide at 1000 mg daily would be readily implementable and could optimize treatment outcomes in drug-susceptible tuberculosis. Clinical trial registration available at www.<BR><B>RESULTS: </B>gov, ID: NCT02410772. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).